Navigation Links
Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
Date:11/13/2009

PLYMOUTH, Mich., Nov. 13 /PRNewswire/ -- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins. The single escalating dose study in healthy volunteers will be the first clinical study conducted by Esperion since the re-establishment of the company in May 2008.

ETC-1002 is being developed to treat dyslipidemia, an early-stage risk factor of coronary artery disease and associated metabolic syndromes. The compound targets lipid metabolism in two ways: first, by inhibiting fatty acid and cholesterol synthesis; and second, by enhancing oxidation of fatty acids. ETC-1002 therefore has the potential to lower LDL-C and triglycerides and also to increase HDL-C.

"Our pre-clinical research related to ETC-1002 has been very promising, and we are pleased to advance this new product candidate to clinical development. ETC-1002 is the flagship product of our dyslipidemia program, and it will also be the first product in our pipeline to reach clinical-stage development," said Roger Newton, PhD, FAHA, president and CEO of Esperion Therapeutics. "Just over a year and a half following the re-establishment of Esperion, we continue to progress toward our goal of bringing breakthrough cardiovascular and metabolic disease therapies to market."

Cardio-metabolic diseases are the leading cause of morbidity and mortality among men and women in industrialized countries around the world.

"We are very well positioned to move ahead with the development effort for ETC-1002 as we also advance our other promising pre-clinical research programs in both acute and chronic therapies to treat cardiovascular and metabolic disorders," Mr. Newton added.

About Esperion Therapeutics

Esperion Therapeutics, Inc. discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases. The company intends to commercialize innovative, first-in-class therapies focused on promoting cardio-metabolic health. For more information please visit www.esperion.com.

SOURCE Esperion Therapeutics


'/>"/>
SOURCE Esperion Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
2. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
3. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
4. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
5. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
6. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
7. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
10. Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
11. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
(Date:6/22/2016)... June 22, 2016 Cell Applications, Inc. ... them to produce up to one billion human ... within one week. These high-quality, consistent stem cells ... cells and spend more time doing meaningful, relevant ... proprietary, high-volume manufacturing process that produces affordable, reliable ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):